Study finds men more likely to fall sick, die from 3 common health conditions
hypertension
,
diabetes
, and
HIV/AIDS
as compared to women, according to a new study. However, compared to women, men were found to be less likely to seek medical care and adhere to treatment for these common health conditions due to norms related to masculinity and healthcare financing.
Men were also more likely to smoke, while women were more likely to be obese and engage in unsafe sex, the study, published in the journal
PLOS Medicine
, found.
The research highlights sex-based differences at each step of the "health pathway", which includes being exposed to a risk factor -- such as smoking -- developing a condition, diagnosis, treatment and death, study authors said.
"Most of these differences are not explained by sex (biology) alone, but by socially-constructed gender -- highlighting the importance of taking a gender justice approach to reducing health inequities. A gender analysis can help to shape systems of health for all," Kent Buse, co-founder of Global 50/50, a UK-based research initiative seeking to achieve gender equality in
global health
, said.
The findings are in line with those from previous studies showing men using fewer preventive, diagnostic, and treatment services for conditions such as HIV and COVID-19, compared to women.
The study found that men and women received different care for hypertension in 200 countries.
Also in 39 countries such as Afghanistan, Bangladesh, Ecuador and Ethiopia, men and women received different care for diabetes, and in 76 countries, including Australia, Chile, Italy and Lesotho, they received different care for HIV.
Overall, the authors said strategies need to be developed for encouraging men to participate in preventive and health care services.
"We have long advocated the benefits of publishing sex disaggregated data. As our Gendered Health Pathways demonstrates, such data can reveal where the health journeys of men and women diverge be it in relation to the risk factors they are exposed to, their health care seeking behaviours or their experiences in health care systems. That is an important first step towards
health equity
," Buse said.
"Males had significantly higher prevalence rates of conditions in 56 per cent of countries for HIV and AIDS, 30 per cent for diabetes, and four per cent for hypertension," the authors wrote.
"Females, on the other hand, had significantly higher prevalence rates of conditions in 14 per cent of countries for HIV and AIDS, five per cent for diabetes, and only in India for hypertension," they wrote.
Further, compared to women, death rates were found to be higher among men in 131 countries (64 per cent) for HIV/AIDS, 107 for hypertension (53 per cent) and 100 for diabetes (49 per cent).
Death rates among women were higher, compared to men, in 25 countries for HIV/AIDS, nine for diabetes and only in the United Arab Emirates for hypertension, the study found.
Women were also seen to have higher rates of diagnosis, treatment, and control.
For the study, data on risk factors, disease prevalence, and death rates were obtained from the Global Burden of Disease (GBD) dataset.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 hours ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Time of India
2 hours ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Time of India
3 hours ago
- Time of India
Hepatitis: Adults Can Also Get Vaccinated If They Missed The Jab In Childhood
Nagpur: As the world observes World Hepatitis Day on July 28, liver disease specialists in Nagpur are urging citizens to act before it's too late — highlighting that Hepatitis B vaccination is not just for children. Adults who missed their shots earlier in life can — and should — get vaccinated now, say doctors. Dr Piyush Marudwar, consultant gastroenterologist and liver transplant physician, said that even today, millions of adults remain unaware that the Hepatitis B vaccine is safe, effective, and easily available at any age. "Hepatitis may be silent, but our response must be loud. Awareness, timely screening, and vaccination are our strongest tools in defeating this global health challenge," said Dr Marudwar. Adding a local perspective, Dr Amol Samarth, gastroenterologist and hepatologist at Super Specialty Hospital, Nagpur, said that hepatitis remains an underdiagnosed but serious threat in Vidarbha, especially because of late testing. "In Nagpur, we are seeing a growing number of patients diagnosed with Hepatitis B and C during evaluations for other illnesses. Unfortunately, many reach us when liver damage has already progressed. Routine screening and adult vaccination are the most effective ways to prevent this," said Dr Samarth. He added that public hospitals like Super Specialty Hospital offer affordable screening and consultation facilities, and that both Hepatitis B vaccination and antiviral treatment are widely accessible in Nagpur now. This year's theme, 'Hepatitis Can't Wait', underscores the urgency of acting early. Doctors warn that the post-Covid disruption in routine health check-ups has led to delays in hepatitis detection and follow-up care. "Hepatitis is one of the leading causes of end-stage liver disease and the need for liver transplantation in India," said Dr Rahul Saxena, secretary of ZTCC Nagpur and a prominent liver transplant surgeon. "Nagpur is gradually becoming a liver transplant-ready city with better awareness and infrastructure. But to reduce the burden, we must focus on prevention," he said. "Hepatitis B has a safe and effective vaccine, and Hepatitis C is now curable with oral medications. Still, many patients present late due to lack of awareness or stigma," Dr Saxena added. All specialists emphasised that testing for hepatitis should be as common as checking for diabetes or blood pressure, especially for high-risk groups such as healthcare workers, pregnant women, dialysis patients, and those who've had blood transfusions.
